A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007762-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the efficacy of 160 mg and 80 mg of subcutaneous (SC) rilonacept therapy compared to placebo in the prophylaxis of flares in subjects with intercritical gout initiating therapy with allopurinol.


Critère d'inclusion

  • Gout flare

Liens